Comparison of allogeneic hematopoietic stem cell transplantation (HCT) with CAR T-cells in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL)

Study type:

Study number:

Type of Stem Cell Treatment:

Allogeneic

CAR T

Diseases:

Non-Hodgkin’s Lymphoma (NHL)

Short title:

TRANSCART

Primary objective:

Key inclusion criteria:

Country:

All EBMT member countries

Principal investigator:

Bertram GLASS

EBMT Study coordinator:

Eva MICHEL

Study coordinator email:

eva.michel@ebmt.org

EBMT Study Unit:

Paris Study Unit

Reason for processing personal data:

Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.

Categories of personal data collected:

DOB/YOB, gender

Medical data already reported to the EBMT Registry

Study Specific Questionnaire (MED-C)

Recipients who may access the data:

Paris Study Unit

3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Article 6 lawful basis for processing personal data:

Article 6.1 (a) - Consent (Collection)

Article 9 basis for processing special category data:

Article 9(2) (a) - Consent (Collection)

Rights available to individuals:

Access

Data portability

Rectification

Objection

Deletion

Is a Data Protection Impact Assessment required?:

DPIA performed for EBMT Registry (WP & NIS Studies)

Retention Schedule (if possible):

at least 5 years after the final report or first publication of study results